3
Announcements
Trials
Browse
Landscape
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
22
Prostatic Neoplasms, Castration-Resistant
4
Non-metastatic Castration-resistant Prostate Cancer
4
Prostatic Diseases
2
Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Hormone-sensitive Prostate Cancer
2
Male Urogenital Diseases
2
Biochemically Recurrent Prostate Cancer
2
Urogenital Neoplasms
1
Urogenital Diseases
1
Refractory or Relapsed Solid Tumors
1
Prostate Cancer Non-Metastatic
1
Non-metastatic Prostate Cancer
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
High-Risk Localized Prostate Cancer
1
Healthy Volunteers
1
Genital Diseases, Male
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms
1
Advanced Solid Tumor
1
Interventions
darolutamide
2
Docetaxel
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
×
darolutamide
×
Clear all
NCT07395804
2026-05-29
23146
Bayer
Recruiting
500 enrolled
NCT06661122
2026-05-19
HAYATE
Bayer
Recruiting
100 enrolled